[go: up one dir, main page]

CL2014002986A1 - Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k. - Google Patents

Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.

Info

Publication number
CL2014002986A1
CL2014002986A1 CL2014002986A CL2014002986A CL2014002986A1 CL 2014002986 A1 CL2014002986 A1 CL 2014002986A1 CL 2014002986 A CL2014002986 A CL 2014002986A CL 2014002986 A CL2014002986 A CL 2014002986A CL 2014002986 A1 CL2014002986 A1 CL 2014002986A1
Authority
CL
Chile
Prior art keywords
chromen
hydroxy
alkyl
derivatives
optionally substituted
Prior art date
Application number
CL2014002986A
Other languages
English (en)
Inventor
Jayaraman Venkat Raman
Swaroop Kumar Venkata Satya Vakkalanka
Original Assignee
Rhizen Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002986(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Rhizen Pharmaceuticals Sa filed Critical Rhizen Pharmaceuticals Sa
Publication of CL2014002986A1 publication Critical patent/CL2014002986A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrane Compounds (AREA)
CL2014002986A 2012-05-04 2014-11-04 Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k. CL2014002986A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1737CH2012 2012-05-04
US201261671956P 2012-07-16 2012-07-16

Publications (1)

Publication Number Publication Date
CL2014002986A1 true CL2014002986A1 (es) 2015-01-09

Family

ID=54193684

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002986A CL2014002986A1 (es) 2012-05-04 2014-11-04 Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.

Country Status (24)

Country Link
US (1) US9309216B2 (es)
EP (1) EP2844647B1 (es)
JP (2) JP6290186B2 (es)
KR (1) KR102073181B1 (es)
CN (2) CN104507922B (es)
AP (1) AP3547A (es)
AU (1) AU2013255469B2 (es)
BR (1) BR112014027470A2 (es)
CA (1) CA2871000C (es)
CL (1) CL2014002986A1 (es)
CO (1) CO7141413A2 (es)
CY (1) CY1123456T1 (es)
EA (1) EA032812B1 (es)
IL (1) IL235181A (es)
MX (1) MX365250B (es)
MY (1) MY171207A (es)
NZ (1) NZ701198A (es)
PH (1) PH12014502453B1 (es)
PL (1) PL2844647T3 (es)
RS (1) RS61035B1 (es)
SG (1) SG11201407184PA (es)
SI (1) SI2844647T1 (es)
WO (1) WO2013164801A1 (es)
ZA (1) ZA201407769B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
US10130635B2 (en) * 2012-05-04 2018-11-20 Rhizen Pharmaceuticals Sa Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
RS61035B1 (sr) * 2012-05-04 2020-12-31 Rhizen Pharmaceuticals S A Proces za dobijanje optički čistih i opciono supstituisanih 2-(1-hidroksi-alkil)-hromen-4-on derivata i njihova upotreba za dobijanje lekova
US9790224B2 (en) 2013-06-07 2017-10-17 Rhizen Pharmaceuticals Sa Dual selective PI3 delta and gamma kinase inhibitors
MX374653B (es) * 2014-06-27 2025-03-06 Rhizen Pharmaceuticals Sa Derivados de cromeno sustituidos como inhibidores duales selectivos de proteínas cinasas pi3 delta y gamma.
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP2018521044A (ja) * 2015-07-23 2018-08-02 ファーマケア，インク． リシルオキシダーゼ様２阻害剤とその使用
US10588900B2 (en) 2016-02-09 2020-03-17 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2023130334A1 (zh) * 2022-01-07 2023-07-13 同润生物医药(上海)有限公司 一种色烯-4-酮化合物及其中间体的制备方法
CN116444521A (zh) * 2022-01-07 2023-07-18 同润生物医药(上海)有限公司 一种色烯-4-酮化合物及其中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
PE20060426A1 (es) * 2004-06-02 2006-06-28 Schering Corp DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
RS61035B1 (sr) * 2012-05-04 2020-12-31 Rhizen Pharmaceuticals S A Proces za dobijanje optički čistih i opciono supstituisanih 2-(1-hidroksi-alkil)-hromen-4-on derivata i njihova upotreba za dobijanje lekova
AU2013285081B2 (en) * 2012-07-04 2017-01-12 Rhizen Pharmaceuticals Sa Selective PI3K delta inhibitors

Also Published As

Publication number Publication date
US9309216B2 (en) 2016-04-12
RS61035B1 (sr) 2020-12-31
CN108084138A (zh) 2018-05-29
BR112014027470A2 (pt) 2017-06-27
AU2013255469A1 (en) 2014-11-13
HK1203964A1 (en) 2015-11-06
AU2013255469B2 (en) 2017-10-12
SG11201407184PA (en) 2014-12-30
PH12014502453B1 (en) 2019-07-03
KR20150006876A (ko) 2015-01-19
MX365250B (es) 2019-05-28
PH12014502453A1 (en) 2015-03-16
CO7141413A2 (es) 2014-12-12
CY1123456T1 (el) 2022-03-24
CA2871000A1 (en) 2013-11-07
AP2014008087A0 (en) 2014-11-30
AP3547A (en) 2016-01-14
EP2844647A1 (en) 2015-03-11
ZA201407769B (en) 2016-05-25
NZ701198A (en) 2016-09-30
JP2018039849A (ja) 2018-03-15
IL235181A (en) 2017-12-31
MX2014013426A (es) 2015-05-11
KR102073181B1 (ko) 2020-02-04
WO2013164801A1 (en) 2013-11-07
CA2871000C (en) 2021-10-19
EA201491818A1 (ru) 2015-04-30
CN104507922A (zh) 2015-04-08
SI2844647T1 (sl) 2020-12-31
JP6290186B2 (ja) 2018-03-07
MY171207A (en) 2019-10-02
EA032812B1 (ru) 2019-07-31
US20150087699A1 (en) 2015-03-26
PL2844647T3 (pl) 2021-01-25
JP2015515975A (ja) 2015-06-04
CN104507922B (zh) 2018-02-09
EP2844647B1 (en) 2020-07-22

Similar Documents

Publication Publication Date Title
CL2014002986A1 (es) Proceso para la preparacion de compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona opticamente puros y opcionalmente sustituidos; compuestos derivados de 2-(1-hidroxi-alquil)-cromen-4-ona; composicion farmaceutica que los comprende; y su uso para preparar compuestos inhibidores de pi3k.
CL2013001947A1 (es) Composicion farmaceutica que comprende pioglitazona; uso de pioglitazona para tratar alzheimer; composicion que comprende pioglitazona.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
GT201300153A (es) Formas cristalinas de 5-cloro-n2-(2-isopropoxi-5-metil-4-piperidin-4-il-fenil)- n4-[2-(propan-2-sulfonil)-fenil pirimidim-2,4-diamina
CO6940429A2 (es) Compuestos heterocíclicos, medicamentos que los contienen, uso de aquellos y procesos para su preparación
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
CL2013001604A1 (es) Compuestos derivados de pirimidinona sustituida; composicion farmaceutica que los comprende; su uso para tratar la enfermedad de alzheimer y la aterosclerosis.
UY35467A (es) Compuestos orgánicos
MX2015012456A (es) Compuestos heterociclicos y usos de los mismos.
MX2015004771A (es) Metodos para tratar cancer.
CL2014001793A1 (es) Compuestos derivados de 1,3,5-triazinas sustituidas y sus sales, como inhibidores de la idh2 mutante; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer.
CL2014003566A1 (es) Compuestos derivados de 7h-pirrolo[2,3-d]pirimidinas 4-(amimo-sustituidas), inhibidores de lrrk2; composicion farmaceutica que los comprende; y metodo para tratar la enfermedad de parkinson.
CL2014000183A1 (es) Formulación farmacéutica que contienen anticuerpos anti-pcsk9; metodo para preparar dicha formulación.
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
GT201400144A (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
UY35210A (es) Inhibidores de autotaxina
BR112014007134A2 (pt) usos de um composto da fórmula (b), compostos, composição farmacêutica, método de preparação do composto e uso de uma quantidade efetiva de um composto
ECSP12012334A (es) Morfolinopirimidinas y su uso en terapia
CR20140275A (es) Triazolopiridinas sustituidas
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
ECSP16059106A (es) Composiciones de liberación retardada de linaclotida
CO6920294A2 (es) Derivados de estra-1,3,5(10),16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos